000661 长春高新
已收盘 08-23 15:00:00
资讯
新帖
简况
长春高新：公司已经按照最新报表格式披露了相关定期报告，如后续涉及相关内容会对应填报相关科目
证券之星 · 08-23 18:06
长春高新：公司已经按照最新报表格式披露了相关定期报告，如后续涉及相关内容会对应填报相关科目
长春高新：如有达到披露标准的相关事宜，公司会按照法律法规要求进行审议披露
证券之星 · 08-22
长春高新：如有达到披露标准的相关事宜，公司会按照法律法规要求进行审议披露
3年市值跌没1783亿，“东北药茅”的生长激素不灵了？
市场资讯 · 08-20
3年市值跌没1783亿，“东北药茅”的生长激素不灵了？
长春高新：8月19日高管叶朋增持股份合计1.11万股
证券之星 · 08-20
长春高新：8月19日高管叶朋增持股份合计1.11万股
长春高新净利润十年来首度下滑降幅超20% 短效水针重演集采旧事生长激素逻辑生变？|医药半年报
新浪证券 · 08-20
长春高新净利润十年来首度下滑降幅超20% 短效水针重演集采旧事生长激素逻辑生变？|医药半年报
长春高新(000661.SZ)：聚乙二醇重组人生长激素新规格新适应症上市申请获批
智通财经 · 08-19
长春高新(000661.SZ)：聚乙二醇重组人生长激素新规格新适应症上市申请获批
长春高新最新公告：子公司长效生长激素新规格新适应症上市申请获得批准
证券之星 · 08-19
长春高新最新公告：子公司长效生长激素新规格新适应症上市申请获得批准
中报净利润同比下降20.4% 长春高新应对“十年之痒”有三条路可走
每日经济新闻 · 08-19
中报净利润同比下降20.4% 长春高新应对“十年之痒”有三条路可走
长春高新（000661）8月16日主力资金净卖出6729.73万元
证券之星 · 08-19
长春高新（000661）8月16日主力资金净卖出6729.73万元
【机构调研记录】泓德基金调研伟星股份、长春高新等4只个股（附名单）
证券之星 · 08-19
【机构调研记录】泓德基金调研伟星股份、长春高新等4只个股（附名单）
【机构调研记录】浙商基金调研长春高新、吉祥航空
证券之星 · 08-19
【机构调研记录】浙商基金调研长春高新、吉祥航空
【机构调研记录】汇安基金调研伟星股份、长春高新
证券之星 · 08-19
【机构调研记录】汇安基金调研伟星股份、长春高新
【机构调研记录】华富基金调研长春高新、盛美上海等4只个股（附名单）
证券之星 · 08-19
【机构调研记录】华富基金调研长春高新、盛美上海等4只个股（附名单）
中国银河：给予长春高新买入评级
证券之星 · 08-19
中国银河：给予长春高新买入评级
长春高新：目前市场环境下，对于地产业务能否剥离事宜，更重要的是需要有具备实力切有合理购买意向的收购方
证券之星 · 08-18
长春高新：目前市场环境下，对于地产业务能否剥离事宜，更重要的是需要有具备实力切有合理购买意向的收购方
德邦证券：给予长春高新买入评级
证券之星 · 08-18
德邦证券：给予长春高新买入评级
长春高新（000661）2024年中报简析：增收不增利
证券之星 · 08-17
长春高新（000661）2024年中报简析：增收不增利
长春高新：8月16日高管姜云涛、王志刚、李秀峰、朱兴功、叶朋、李洪谕、解兵、刘永川、李姝增持股份合计20.56万股
证券之星 · 08-16
长春高新：8月16日高管姜云涛、王志刚、李秀峰、朱兴功、叶朋、李洪谕、解兵、刘永川、李姝增持股份合计20.56万股
长春高新(000661.SZ)相关董监高人员完成增持股份20.56万股
智通财经 · 08-16
长春高新(000661.SZ)相关董监高人员完成增持股份20.56万股
长春高新：8月16日接受机构调研，包括知名机构淡水泉，彤源投资，正圆投资的多家机构参与
证券之星 · 08-16
长春高新：8月16日接受机构调研，包括知名机构淡水泉，彤源投资，正圆投资的多家机构参与
加载更多
公司概况
公司名称：
长春高新技术产业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-18
主营业务：
长春高新技术产业(集团)股份有限公司的主营业务为生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品为聚乙二醇重组人生长激素注射液、重组人生长激素、注射用重组人促卵泡激素、冻干水痘减毒活疫苗、人用狂犬病疫苗、血栓心脉宁片、银花泌炎灵片等。
发行价格：
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":79.59,"timestamp":1724396598000,"preClose":79.64,"halted":0,"volume":3597887,"delay":0,"floatShares":398000000,"shares":404000000,"eps":10.1178,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.05,"latestTime":"08-23 15:00:00","open":79.18,"high":80.63,"low":79.18,"amount":288000000,"amplitude":0.0182,"askPrice":79.6,"askSize":64,"bidPrice":79.59,"bidSize":129,"shortable":0,"etf":0,"ttmEps":10.1178,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":79.64,"symbolType":"stock","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":87.6,"lowLimit":71.68,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":404423090,"pbRate":1.47,"roa":"--","roe":"7.73%","epsLYR":11.21,"committee":0.231156,"marketValue":32188000000,"floatMarketCap":31711000000,"peRate":7.866335,"changeRate":-0.0006,"turnoverRate":0.009,"status":1},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2461056530","title":"长春高新：公司已经按照最新报表格式披露了相关定期报告，如后续涉及相关内容会对应填报相关科目","url":"https://stock-news.laohu8.com/highlight/detail?id=2461056530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461056530?lang=zh_cn&edition=full","pubTime":"2024-08-23 18:06","pubTimestamp":1724407593,"startTime":"0","endTime":"0","summary":"长春高新董秘：公司严格按照会计准则要求和实际情况确认坏账计提标准，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300036019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0075","BK0046","BK0057","000661"],"gpt_icon":0},{"id":"2461539359","title":"长春高新：如有达到披露标准的相关事宜，公司会按照法律法规要求进行审议披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2461539359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461539359?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:15","pubTimestamp":1724318126,"startTime":"0","endTime":"0","summary":"长春高新董秘：您好，相关金额变动主要是计提利息所致，谢谢！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200030909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0239","BK0057","BK0046","BK0188","BK0075"],"gpt_icon":0},{"id":"2460600226","title":"3年市值跌没1783亿，“东北药茅”的生长激素不灵了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2460600226","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460600226?lang=zh_cn&edition=full","pubTime":"2024-08-20 21:41","pubTimestamp":1724161260,"startTime":"0","endTime":"0","summary":" 营收同比增长7.63%，净利10年首降。 被称为“东北药茅”的长春高新，在二股东金磊与前妻离婚，给了40亿股权“分手费”备受争议之后，8月16日，又交出了一份十年来净利润增速下滑的半年报。 长春高新主营业务分为生物制品、疫苗、中成药和房地产四大板块，导致公司净利润下降的正是核心子公司——生产生长激素类产品的金赛药业。市值较2021年巅峰时刻的2118亿元缩水了1783亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-08-20/doc-inckiare5298724.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-08-20/doc-inckiare5298724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064131003.USD","LU2580892789.USD","300009","BK0042","BK4585","BK0075","300122","BK0060","BK0070","LU2580892862.HKD","GSK.UK","688276","BK4532","688278","BK0028","BK0057","LU1064130708.USD","BK0239","BK0196","BK4007","GSK","LU1328615791.USD","LU1829250122.USD","BK4588","BK0077","LU2148510915.USD","BK0046","000661","BK0188"],"gpt_icon":0},{"id":"2460009821","title":"长春高新：8月19日高管叶朋增持股份合计1.11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2460009821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460009821?lang=zh_cn&edition=full","pubTime":"2024-08-20 21:01","pubTimestamp":1724158860,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月20日市场公开信息、上市公司公告及交易所披露数据整理，长春高新最新董监高及相关人员股份变动情况：2024年8月19日公司高管叶朋共增持公司股份1.11万股，占公司总股本为0.0027%。变动期间公司股价下跌2.28%，8月19日当日收盘报84.19元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082000036623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","000661","BK0239","BK0046","BK0188","BK0075","BK0028"],"gpt_icon":0},{"id":"2460407688","title":"长春高新净利润十年来首度下滑降幅超20% 短效水针重演集采旧事生长激素逻辑生变？|医药半年报","url":"https://stock-news.laohu8.com/highlight/detail?id=2460407688","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460407688?lang=zh_cn&edition=full","pubTime":"2024-08-20 18:02","pubTimestamp":1724148120,"startTime":"0","endTime":"0","summary":" 近日，长春高新披露2024年半年度报告。公告显示，公司上半年实现营业收入约为66.39亿元，同比增长7.63%；归母净利润约为17.2亿元，同比下降20.4%；对应实现的扣非后归母净利润约为17.37亿元，同比下降19.72%；经营活动产生的现金流量净额为19.77亿元，同比下降2.24%。 结合往期半年度业绩表现看，长春高新利润端为近十年间首次出现同比下滑，且降幅较大。在此之前，长春高新的净利润增速不断放缓，2023年上半年，长春高新的净利润同比仅增长1.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/observe/2024-08-20/doc-inckhwie8577861.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-08-20/doc-inckhwie8577861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000661","159938","09939"],"gpt_icon":0},{"id":"2460033262","title":"长春高新(000661.SZ)：聚乙二醇重组人生长激素新规格新适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2460033262","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460033262?lang=zh_cn&edition=full","pubTime":"2024-08-19 20:29","pubTimestamp":1724070567,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，近日，公司子公司——长春金赛药业有限责任公司(金赛药业”)聚乙二醇重组人生长激素注射液(“长效生长激素”)新规格新适应症上市申请获得国家药品监督管理局批准。经审查，本品符合药品注册的有关要求，批准注册，发给药品注册证书。适应症为：用于性腺发育不全(特纳综合征)所致女孩的生长障碍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1166543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0057","BK0046","BK0028","000661","BK0188","BK0239","BK0075"],"gpt_icon":0},{"id":"2460082303","title":"长春高新最新公告：子公司长效生长激素新规格新适应症上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2460082303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460082303?lang=zh_cn&edition=full","pubTime":"2024-08-19 19:01","pubTimestamp":1724065273,"startTime":"0","endTime":"0","summary":"长春高新公告，近日，公司子公司长春金赛药业有限责任公司聚乙二醇重组人生长激素注射液（简称“长效生长激素”）新规格新适应症上市申请获得国家药监局批准。适应症为用于性腺发育不全（特纳综合征）所致女孩的生长障碍。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900025682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0028","BK0046","BK0239","000661","BK0057","BK0188"],"gpt_icon":0},{"id":"2460777296","title":"中报净利润同比下降20.4% 长春高新应对“十年之痒”有三条路可走","url":"https://stock-news.laohu8.com/highlight/detail?id=2460777296","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460777296?lang=zh_cn&edition=full","pubTime":"2024-08-19 13:15","pubTimestamp":1724044500,"startTime":"0","endTime":"0","summary":" 长春高新，这家曾被誉为“东北药茅”的医药巨头，正面临前所未有的挑战。2024年半年报显示，长春高新净利润同比下降20.4%，这是其上市以来十年内的首次负增长。 长春高新近年来的辉煌业绩主要依赖于子公司金赛药业的生长激素产品。此次半年报中，金赛药业的收入增幅仅为0.25%，净利润更是大幅下滑近20%。这表明，单品独大的问题已经严重威胁到长春高新的持续增长能力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-08-19/doc-inckeanq6490377.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-08-19/doc-inckeanq6490377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000661"],"gpt_icon":0},{"id":"2460729967","title":"长春高新（000661）8月16日主力资金净卖出6729.73万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460729967","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460729967?lang=zh_cn&edition=full","pubTime":"2024-08-19 09:21","pubTimestamp":1724030511,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月16日收盘，长春高新报收于86.15元，下跌3.62%，换手率2.48%，成交量9.87万手，成交额8.5亿元。8月16日的资金流向数据方面，主力资金净流出6729.73万元，占总成交额7.91%，游资资金净流入5110.3万元，占总成交额6.01%，散户资金净流入1619.43万元，占总成交额1.9%。融券方面，融券卖出8400.0股，融券偿还1800.0股，融券余量12.51万股，融券余额1077.77万元。长春高新主营业务：生物制药及中成药的研发、生产和销售,辅以房地产开发、物业管理和服务等业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900002613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","BK0028","BK0075","000661","BK0239","BK0046"],"gpt_icon":0},{"id":"2460723879","title":"【机构调研记录】泓德基金调研伟星股份、长春高新等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2460723879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460723879?lang=zh_cn&edition=full","pubTime":"2024-08-19 08:02","pubTimestamp":1724025729,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月16日披露的机构调研信息，泓德基金近期对4家上市公司进行了调研，相关名单如下：1）伟星股份 个股亮点：公司累计接到防护服等相关拉链订单600万条左右2）长春高新 个股亮点：国内生长激素行业龙头；公司艾塞那肽产品；子公司金赛药业为重组生长激素国内基因重组蛋白药物龙头；创新药伪人参皂苷GQ处于临床2期，艾塞那肽申报待批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900001575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","002003","BK0046","BK0028","000661","BK0188","BK0239","BK0075","BK0253"],"gpt_icon":0},{"id":"2460723812","title":"【机构调研记录】浙商基金调研长春高新、吉祥航空","url":"https://stock-news.laohu8.com/highlight/detail?id=2460723812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460723812?lang=zh_cn&edition=full","pubTime":"2024-08-19 08:02","pubTimestamp":1724025729,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月16日披露的机构调研信息，浙商基金近期对2家上市公司进行了调研，相关名单如下：1）长春高新 个股亮点：国内生长激素行业龙头；公司艾塞那肽产品；子公司金赛药业为重组生长激素国内基因重组蛋白药物龙头；创新药伪人参皂苷GQ处于临床2期，艾塞那肽申报待批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900001576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603885","BK0075","BK0239","BK0057","BK0028","BK0185","BK0188","BK0280","000661","BK0046"],"gpt_icon":0},{"id":"2460723816","title":"【机构调研记录】汇安基金调研伟星股份、长春高新","url":"https://stock-news.laohu8.com/highlight/detail?id=2460723816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460723816?lang=zh_cn&edition=full","pubTime":"2024-08-19 08:02","pubTimestamp":1724025725,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月16日披露的机构调研信息，汇安基金近期对2家上市公司进行了调研，相关名单如下：1）伟星股份 个股亮点：公司累计接到防护服等相关拉链订单600万条左右2）长春高新 个股亮点：国内生长激素行业龙头；公司艾塞那肽产品；子公司金赛药业为重组生长激素国内基因重组蛋白药物龙头；创新药伪人参皂苷GQ处于临床2期，艾塞那肽申报待批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900001569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0253","BK0028","BK0188","002003","BK0046","BK0057","BK0075","000661"],"gpt_icon":0},{"id":"2460723897","title":"【机构调研记录】华富基金调研长春高新、盛美上海等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2460723897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460723897?lang=zh_cn&edition=full","pubTime":"2024-08-19 08:01","pubTimestamp":1724025691,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月16日披露的机构调研信息，华富基金近期对4家上市公司进行了调研，相关名单如下：1）长春高新 个股亮点：国内生长激素行业龙头；公司艾塞那肽产品；子公司金赛药业为重组生长激素国内基因重组蛋白药物龙头；创新药伪人参皂苷GQ处于临床2期，艾塞那肽申报待批。3）中科蓝讯 个股亮点：公司主营业务为无线音频SoC芯片的研发、设计与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900001511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","BK0028","688082","BK0075","000661","BK0239","BK0251","BK0046"],"gpt_icon":0},{"id":"2460240728","title":"中国银河：给予长春高新买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2460240728","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460240728?lang=zh_cn&edition=full","pubTime":"2024-08-19 07:45","pubTimestamp":1724024716,"startTime":"0","endTime":"0","summary":"中国银河证券股份有限公司程培,宋丽莹近期对长春高新进行研究并发布了研究报告《2024年中报业绩点评：转型升级致利润承压，短期费用投入较高》，本报告对长春高新给出买入评级，当前股价为86.15元。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为188.52。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900001340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","601881"],"gpt_icon":0},{"id":"2460711798","title":"长春高新：目前市场环境下，对于地产业务能否剥离事宜，更重要的是需要有具备实力切有合理购买意向的收购方","url":"https://stock-news.laohu8.com/highlight/detail?id=2460711798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460711798?lang=zh_cn&edition=full","pubTime":"2024-08-18 22:00","pubTimestamp":1723989638,"startTime":"0","endTime":"0","summary":"谢谢长春高新董秘：目前网站改版工作持续推进中，会尽快上线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081800002433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0075","000661","BK0028","BK0057","BK0188"],"gpt_icon":0},{"id":"2460960927","title":"德邦证券：给予长春高新买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2460960927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460960927?lang=zh_cn&edition=full","pubTime":"2024-08-18 15:45","pubTimestamp":1723967116,"startTime":"0","endTime":"0","summary":"德邦证券股份有限公司周新明,吴明华近期对长春高新进行研究并发布了研究报告《短期业绩承压，多元化产品布局助力长期发展》，本报告对长春高新给出买入评级，当前股价为86.15元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为188.52。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081800001382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000661"],"gpt_icon":0},{"id":"2460222047","title":"长春高新（000661）2024年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2460222047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460222047?lang=zh_cn&edition=full","pubTime":"2024-08-17 06:07","pubTimestamp":1723846057,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期长春高新发布2024年中报。根据财报显示，长春高新增收不增利。截至本报告期末，公司营业总收入66.39亿元，同比上升7.63%，归母净利润17.2亿元，同比下降20.4%。其中，子公司金赛药业实现收入 51.52亿元，较上年同期增长 0.25%；实现归属于母公司所有者的净利润 17.69 亿元，较上年同期降低 19.49%。报告期内，研发投入 11.38亿元，同比增长 10.18%；其中研发费用 8.87亿元，同比增长26.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081700011274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0046","BK0028","000661","BK0188","BK0239","BK0075"],"gpt_icon":0},{"id":"2459297876","title":"长春高新：8月16日高管姜云涛、王志刚、李秀峰、朱兴功、叶朋、李洪谕、解兵、刘永川、李姝增持股份合计20.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459297876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459297876?lang=zh_cn&edition=full","pubTime":"2024-08-16 19:00","pubTimestamp":1723806054,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月16日市场公开信息、上市公司公告及交易所披露数据整理，长春高新最新董监高及相关人员股份变动情况：2024年8月16日公司董事长,总经理姜云涛、董事,副总经理王志刚、董事,副总经理李秀峰、副总经理,财务总监朱兴功、副总经理叶朋、董事会秘书李洪谕、监事会主席解兵、监事刘永川、职工代表监事李姝共增持公司股份20.56万股，占公司总股本为0.0508%。变动期间公司股价下跌3.62%，8月16日当日收盘报86.15元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600043960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","BK0028","BK0075","000661","BK0239","BK0046"],"gpt_icon":0},{"id":"2459941962","title":"长春高新(000661.SZ)相关董监高人员完成增持股份20.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459941962","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459941962?lang=zh_cn&edition=full","pubTime":"2024-08-16 18:39","pubTimestamp":1723804789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，截至2024年8月16日收市，本次增持计划主体(部分董事、监事、高级管理人员)通过深圳证券交易所集中竞价方式在二级市场合计增持公司股份20.56万股，占公司总股本的比例为0.0508%，合计增持股份金额为1766.77万元，本次增持计划已实施完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0046","BK0057","BK0188","BK0028","BK0075","BK0239"],"gpt_icon":0},{"id":"2459729986","title":"长春高新：8月16日接受机构调研，包括知名机构淡水泉，彤源投资，正圆投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2459729986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459729986?lang=zh_cn&edition=full","pubTime":"2024-08-16 18:01","pubTimestamp":1723802502,"startTime":"0","endTime":"0","summary":"报告期内，研发投入 11.38亿元，同比增长 10.18%；其中研发费用 8.87亿元，同比增长26.16%。报告期内，管理费用 5.51 亿元，同比增长 53.71%。该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为188.52。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600039944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0028","BK0188","BK0239","BK0075","000661","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","stockEarnings":[{"period":"1week","weight":-0.0761},{"period":"1month","weight":-0.1157},{"period":"3month","weight":-0.2906},{"period":"6month","weight":-0.3383},{"period":"1year","weight":-0.4078},{"period":"ytd","weight":-0.433}],"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","perCapita":"2933股","boardName":"医药制造业","registeredCapital":"40442万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 长春高新技术产业(集团)股份有限公司的主营业务为生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品为聚乙二醇重组人生长激素注射液、重组人生长激素、注射用重组人促卵泡激素、冻干水痘减毒活疫苗、人用狂犬病疫苗、血栓心脉宁片、银花泌炎灵片等。","serverTime":1724614401345,"listedPrice":8.8,"stockholders":"135814人(较上一季度增加3.87%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}